胰臟癌的發生率節節升高，但是超過八成的病人診斷時都已經是局部侵襲性癌症或是晚期轉移疾病。過去數十年間，雖然藥物治療及手術技術有長足發展，但是相較於其他癌症，此疾病的五年存活率仍無法令人滿意，與其他惡性腫瘤有相當大的差距。本研究主要分析南臺灣單一醫學中心以多專科團隊為基礎的完整治療計畫下，胰臟癌治療成績的進展。本研究納入自2012-2017年間於南台灣一家醫學中心診斷及接受完整治療的病人，總共收錄490位病人，所接受的治療皆根據多專科團隊所擬定的流程。本研究發現，在完整的多專科團隊介入治療之下，可有效提升胰臟癌治療成果，使五年存活率可超過10%，同時超過五成之病人可存活超過一年，為目前的頂尖成績。在次族群分析中發現，在可切除之病人中，若可以達到完整的R0切除，可使病人有較長之存活率。而在局部侵襲性或是轉移性胰臟癌病人，在接受一段時間的全身性治療後，若可以進行降階或救援性手術治療，亦可大幅提升胰臟癌病人之存活率

Pancreatic cancer is a disease which was difficult to diagnosed in early stage, which cause that most of the patients had advanced or metastatic disease upon diagnosis. The 5-year survival was still poor compared with other malignant disease. Many systemic treatment or surgical interventional methods were developed in the past decades, but the results were still unsatisfactory. The study aimed to analyze the improvement of the survival of the pancreatic cancer patients who received the whole treatment course in a tertiary center under a multidisciplinary team (MDT) based comprehensive treatment algorithm in Southern Taiwan. Patients who were diagnosed as pancreatic adenocarcinoma with tissue proof in 2012-2017 and received the complete treatment course in a tertiary medical center in Southern Taiwan were enrolled in this study. Total four hindered ninety patients were enrolled. In all patients regardless of the diagnosed year and the treatment, the 5-yar survival rate was 32.68% and median survival 32.89 months in stage I, 15.21% and median survival 21.43 months in stage II, 4.45% and median survival 12.71 months in stage III, 0.74% and median survival 6.18 months in stage IV patients. Overall, more than 50% patients could survive more than 1 year. In subgroup analysis, patients with resectable disease who received surgical resection, we found that R0 resection was a independent factor in overall survival. For those who had locally advanced or metastatic disease, in those who received conversion or salvage surgery after systemic treatment could have a longer survival. In conclusion, under the comprehensive treatment algorithm and MDT-based treatment, it could definitely improve the overall survival of the pancreatic cancer patients.

1. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 2021 Jul;18(7):493-502.
2. Pancreatic cancer action network. https://www.pancan.org/facing-pancreatic-cancer/living-with-pancreatic-cancer/advanced-cancer/. Accessed 19 September 2021.
3. Siegel RL. Mille KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
4. Cheng TM, Huang SP, Liao WC, et al. Incidence and mortality of pancreatic cancer on a rapid rise in Taiwan, 1999-2012. Cancer Epidemiol. 2017 Aug; 49:75-84.
5. Pereira SP, Oldfield L, Ney A, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710.
6. Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020 Jun 27;395(10242):2008-2020.
7. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947.
8. Retraction of Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. Am J Clin Nutr 2013;98(6):1425-32.
9. Rebours V, Gaujoux S, Assignies GD, et al. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). Clin Cancer Res. 2015 Aug 1;21(15):3522-8.
10. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995 May 24-31;273(20):1605-9.
11. Andersen DK, Korc M, Petersen GM, et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017 May;66(5):1103-1110.
12. Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. Nov-Dec 2012;18(6):485-91.
13. Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003 Nov;58(5):690-5.
14. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012 Jun;3(2):105-19.
15. Grollman EF, Kobata A, Ginsburg V. An enzymatic basis for Lewis blood types in man. J Clin Invest. 1969 Aug;48(8):1489-94.
16. Azizian A, Rühlmann F, Krause T, et al. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020 Jan 28;10(1):1332.
17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.
18. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.
19. Hoff DV, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703.
20. Chiang NJ, Tsai KK, Hsiao CF, et al. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Eur J Cancer. 2020 Jan; 124:123-130.
21. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019; 381:317-327.
22. Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Journal of Clinical Oncology 39, no. 3_suppl (January 20, 2021) 378-378
23. Cancer research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/survival#heading-Zero. Accessed 20 September 2021.
24. Henderson SE, Makhijani N, Mace T Henderson SE, Makhijani N, Mace TA. Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models. Pancreas. 2018;47: 937–945
25. Tan CR, Yaffee MP, Jamil LH, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014 Mar 3; 5:88
26. Pietrasz D, Pécuchet N, Garlan F, et al. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res. 2017 Jan 1;23(1):116-123.
27. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999 Jul;65(7):618-23.
28. Okasha H, Elkholy S, El-Sayed R, et al. Real time endoscopic ultrasound elastography and strain ratio in the diagnosis of solid pancreatic lesions. World J Gastroenterol. 2017 Aug 28;23(32):5962-5968.
29. Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010 Jun;251(6):1003-10.
30. Yamamoto T, Uchida Y, Terajima H. Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. Asian J Surg. 2019 Jan;42(1):93-99.
31. Esposito I, Kleeff J, Bergmann, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008 Jun;15(6):1651-60
32. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008 Jan;143(1):75-83
33. Philip PA, Lacy J, Portales F, Sobrero A, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294
34. Epstein JD, Kozak G, Fong ZV, et al. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2017 Nov;116(6):658-664.
35. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020 Jun 1;38(16):1763-1773
36. Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). Journal of Clinical Oncology 37, no. 4_suppl (February 01, 2019) 189-189.
37. Alliance A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer. Accessed 25 September 2021.
38. Ahmad SA, Duong Mai, Sohal DPS, et al. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 Sep 1;272(3):481-486
39. Sohal DPS, Doung M, Ahmad SA, et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Mar 1;7(3):421-427
40. Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med. 2019 Nov 12;8(11):1945
41. American Cancer Society, Cancer Facts and Figures 2014-2021. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Accessed 20 September 2021
42. Johns Hopkins medicine Pancreatic Cancer Prognosis. https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis. Accessed 20 September 2021